Investigation of whole blood and urine monoamines in autism

Hérault, Jósiane; Martineau, J.; Perrot-Beaugerie, A.; Jouve, J.; Tournade, H.; Barthélémy, Catherine; G, Lelord; Müh, J.P.

doi:10.1007/bf02098580

Cited by 15 publications

(7 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, Gevi et al (2016) found that 5HT concentrations were significantly lower in urine samples from 30 children with ASD compared with 30 matched controls. Thus, our finding that ASD children have elevated urinary 5HT levels is consistent with the results of Hérault et al (1993).…”

Section: Discussionsupporting

confidence: 89%

“…However, whether urinary 5HT levels could be used as an ASD biomarker is a controversial topic. Hérault et al (1993) examined monoamine concentrations in urine samples from 23 children with ASD and 59 matched TD children, and they detected higher 5HT levels in the ASD group. However, Gevi et al (2016) found that 5HT concentrations were significantly lower in urine samples from 30 children with ASD compared with 30 matched controls.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Altered Urinary Amino Acids in Children With Autism Spectrum Disorders

Liu

Zhou

et al. 2019

Front. Cell. Neurosci.

View full text Add to dashboard Cite

Autism spectrum disorders (ASD) affect 1% of children. Although there is no cure, early diagnosis and behavioral intervention can relieve the symptoms. The clinical heterogeneity of ASD has created a need for improved sensitive and specific laboratory diagnostic methods. Liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based analysis of the metabolome has shown great potential to uncover biomarkers for complex diseases such as ASD. Here, we used a two-step discovery–validation approach to identify potential novel metabolic biomarkers for ASD. Urine samples from 57 children with ASD and 81 matched children with typical development (TD) were analyzed by LS-MS/MS to assess differences in urinary amino acids and their metabolites (referred to as UAA indicators). A total of 63 UAA indicators were identified, of which 21 were present at significantly different levels in the urine of ASD children compared with TD children. Of these 21, the concentrations of 19 and 10 were higher and lower, respectively, in the urine of ASD children compared with TD children. Using support vector machine modeling and receiver operating characteristic curve analysis, we identified a panel of 7 UAA indicators that discriminated between the samples from ASD and TD children (lysine, 2-aminoisobutyric acid, 5-hydroxytryptamine, proline, aspartate, arginine/ornithine, and 4-hydroxyproline). Among the significantly changed pathways in ASD children were the ornithine/urea cycle (decreased levels of the excitatory amino acid aspartate [p = 2.15 × 10-10] and increased arginine/ornithine [p = 5.21 × 10-9]), tryptophan metabolism (increased levels of inhibitory 5-hydroxytryptamine p = 3.62 × 10-9), the methionine cycle (increased methionine sulfoxide [p = 1.46 × 10-10] and decreased homocysteine [p = 2.73 × 10-7]), and lysine metabolism (reduced lysine [p = 7.8 × 10-9], α-aminoadipic acid [p = 1.16 × 10-9], and 5-aminovaleric acid [p = 1.05 × 10-5]). Collectively, the data presented here identify a possible imbalance between excitatory and inhibitory amino acid metabolism in ASD children. The significantly altered UAA indicators could therefore be potential diagnostic biomarkers for ASD.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionmentioning

confidence: 99%

Altered Urinary Amino Acids in Children With Autism Spectrum Disorders

Liu

Zhou

et al. 2019

Front. Cell. Neurosci.

View full text Add to dashboard Cite

show abstract

“…Hyperserotonemia is also associated with restricted and repetitive patterns of behaviors (motor or verbal stereotypies) and interests [24,72,82]. Furthermore, Sacco et al [82] noted a negative correlation between 5-HT levels and neurodevelopmental delay and a positive correlation with stereotyped behaviors; however, the developmental quotient was not correlated with the levels of 5-HT in Hérault et al [114]. In Chugani et al [69], subjects with normal 5-HT levels had a greater chance of improving in "restricted and repetitive behaviors" ADOS scores than those with hyperserotonemia.…”

Section: Asd Core Symptoms and Neurocognitive Outcomesmentioning

confidence: 95%

A Systematic Review on Autism and Hyperserotonemia: State-of-the-Art, Limitations, and Future Directions

Esposito,

Cruciani,

Zaccaro

et al. 2024

Brain Sciences

View full text Add to dashboard Cite

Hyperserotonemia is one of the most studied endophenotypes in autism spectrum disorder (ASD), but there are still no unequivocal results about its causes or biological and behavioral outcomes. This systematic review summarizes the studies investigating the relationship between blood serotonin (5-HT) levels and ASD, comparing diagnostic tools, analytical methods, and clinical outcomes. A literature search on peripheral 5-HT levels and ASD was conducted. In total, 1104 publications were screened, of which 113 entered the present systematic review. Of these, 59 articles reported hyperserotonemia in subjects with ASD, and 26 presented correlations between 5-HT levels and ASD-core clinical outcomes. The 5-HT levels are increased in about half, and correlations between hyperserotonemia and clinical outcomes are detected in a quarter of the studies. The present research highlights a large amount of heterogeneity in this field, ranging from the characterization of ASD and control groups to diagnostic and clinical assessments, from blood sampling procedures to analytical methods, allowing us to delineate critical topics for future studies.

show abstract

“…Many studies (Young et al 1978;Garnier et al 1986;Launay et al 1987;Minderaa et al 1987;Barthelemy et al 1988;Garreau et al 1988;Barthelemy et al 1989;Minderaa et al 1989;Martineau et al 1991;Martineau et al 1992;Herault et al 1993;Martineau et al 1994;Minderaa et al 1994;Herault et al 1996;Croonenberghs et al 2000;Mulder et al 2009) have focused on neurotransmitter abnormalities in individuals with autism. Abnormalities in various neurotransmitters have been implicated in the development of autism, including serotonin (5-hydroxytryptamine, 5-HT), dopamine (DA), noradrenaline (NA), gamma-aminobutryic acid, glutamate and neuropeptides.…”

Section: Normalise Neurotransmitters and Neurotransmitter Metabolitesmentioning

confidence: 99%

“…A range of neurochemical studies have attempted to examine excretion of urinary NA and / or adrenaline (A) in individuals with autism compared with controls and have yielded inconsistent findings. Three studies found higher levels of NA and/or A in autism compared to controls Herault et al 1993;Martineau et al 1994), while four studies found no differences (Launay et al 1987;Martineau et al 1992;Minderaa et al 1994;Croonenberghs et al 2000). Therefore as outlined in Table 2, the range of neurotransmitter abnormalities that have been shown to occur in autism provide a rationale for the use of CAM products that are claim to normalise neurotransmitter levels and function such as: high dose pyridoxine and magnesium, metabolites and co-factors of the transmethylation and trans-sulphuration cycles (see Figure 1), vitamin C, zinc and secretin.…”

Section: Noradrenalinementioning

confidence: 99%